Valproate Pre-Op Bloods — FRCA Final MCQ
Instant feedback + full explanation. One question, done properly.
Educational content. Not a substitute for clinical judgement or local policy.
Reveal the answer and explanation
Correct answer: B — Blood glucose
Sodium valproate has specific haematological effects: (1) thrombocytopenia (dose-dependent, affects up to 5-18% of patients), (2) impaired platelet function (independent of count), (3) reduced fibrinogen and Factor XIII levels, (4) hepatotoxicity (elevated transaminases, rarely fulminant hepatic failure). Pre-operative FBC (particularly platelet count), LFTs, and coagulation screen should be checked. If platelets are <80 × 10⁹/L or coagulation is abnormal, neuraxial techniques are contraindicated and surgical bleeding risk increases. Valproate should be continued perioperatively (via NG/IV if needed) to prevent seizures.
Reference: BNF – 2025 – Sodium valproate: monitoring requirements; RCOA – 2023 – Paediatric and epilepsy modules